Smith & Nephew SNATS, Inc. (NYSE:SNN) Receives Average Recommendation of “Hold” from Analysts

Smith & Nephew SNATS, Inc. (NYSE:SNN) has received a consensus recommendation of “Hold” from the six research firms that are currently covering the stock, Marketbeat Ratings reports. Five analysts have rated the stock with a hold recommendation and one has assigned a buy recommendation to the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $30.9250.

Several analysts have commented on SNN shares. The Goldman Sachs Group reaffirmed a “buy” rating on shares of Smith & Nephew SNATS in a research report on Monday, May 25th. Canaccord Genuity Group dropped their target price on Smith & Nephew SNATS from $32.00 to $30.00 and set a “hold” rating on the stock in a report on Monday, May 11th. Kepler Capital Markets cut Smith & Nephew SNATS from a “buy” rating to a “hold” rating in a research note on Thursday, June 4th. Sanford C. Bernstein set a $31.85 price target on Smith & Nephew SNATS in a report on Monday, May 11th. Finally, Wall Street Zen upgraded shares of Smith & Nephew SNATS from a “buy” rating to a “strong-buy” rating in a research report on Saturday, July 4th.

Smith & Nephew SNATS Trading Up 3.2%

Shares of SNN opened at $30.77 on Thursday. Smith & Nephew SNATS has a fifty-two week low of $28.56 and a fifty-two week high of $38.79. The firm has a 50-day simple moving average of $30.19 and a 200-day simple moving average of $32.38. The company has a current ratio of 2.57, a quick ratio of 1.25 and a debt-to-equity ratio of 0.60.

Institutional Trading of Smith & Nephew SNATS

Hedge funds have recently made changes to their positions in the company. Garner Asset Management Corp acquired a new position in shares of Smith & Nephew SNATS during the fourth quarter worth about $27,000. Arax Advisory Partners lifted its position in Smith & Nephew SNATS by 142.6% in the fourth quarter. Arax Advisory Partners now owns 968 shares of the medical equipment provider’s stock valued at $32,000 after purchasing an additional 569 shares during the period. Advisors Asset Management Inc. purchased a new stake in Smith & Nephew SNATS in the 4th quarter valued at approximately $36,000. Caitong International Asset Management Co. Ltd purchased a new stake in Smith & Nephew SNATS in the 3rd quarter valued at approximately $41,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new position in Smith & Nephew SNATS during the 4th quarter worth approximately $43,000. Institutional investors and hedge funds own 25.64% of the company’s stock.

Smith & Nephew SNATS Company Profile

Smith & Nephew plc is a global medical technology company specializing in the design, development and manufacture of advanced surgical devices, orthopaedic reconstruction implants, trauma and extremities products, sports medicine solutions and wound care therapies. Founded in 1856 in Hull, United Kingdom, the company has grown through both organic innovation and strategic acquisitions to offer a broad portfolio that addresses patient needs across joint replacement, minimally invasive surgery and wound healing.

In its orthopaedics business, Smith & Nephew provides hip and knee replacement systems, modular joint revision implants and biologic solutions for bone repair.